Research monograph · synthetic 30-amino-acid ghrh(1–29) analog with drug affinity complex (dac) albumin-binding modification
Extended GH Release Studies
This monograph collects what the published literature reports about CJC-1295 DAC — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Because albumin turns over slowly, the linker extends the compound's half-life from minutes into days. That single structural difference is what separates it from standard CJC-1295, and it is the property most research on the compound is built around.
For laboratory research use only — not for human or animal use
Mechanisms
GHRH Receptor Activation
A 30-residue GHRH(1–29) analogue carrying four substitutions that block protease cleavage. The receptor interaction matches native GHRH; the substitutions only determine how long the molecule survives to use it.
Albumin Binding — Half-Life Extension
The drug affinity complex is a maleimidopropionic acid group at Lys8 that binds circulating albumin after injection. Because albumin turns over slowly, half-life extends from minutes into days — this is the entire difference from the non-DAC version.
Downstream IGF-1 Elevation
Sustained rather than pulsatile growth hormone exposure drives continuous hepatic IGF-1 production. Whether that steady profile is preferable to a pulsatile one is the open question separating the two variants.
Studied applications
The albumin linker turns a minutes-long half-life into days, so exposure is continuous rather than pulsed. That is the variable this compound exists to test.
Teichman et al. 2006
Binding circulating albumin creates a slow-release depot. Because albumin turns over slowly, the peptide is released gradually rather than cleared.
Teichman et al. 2006
Activity stays at the GHRH receptor rather than spilling into the ghrelin pathway, which keeps the pituitary's own feedback intact.
Teichman et al. 2006
Animal models measure whether sustained upstream stimulation restores growth trajectories, using the non-DAC variant as the comparison.
Alba et al. 2006
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Molecular weight | 3,647.10 g/mol |
|---|---|
| Molecular formula | C152H252N44O42 |
| Physical form | Lyophilized powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for up to 24 months |
| Solubility | Water-soluble |
| Available sizes | 5mg |
FAQ
The DAC variant adds a drug affinity complex — a chemical linker that binds circulating albumin. Because albumin turns over slowly, the linker extends the compound's half-life from minutes into days. That single structural difference is what separates it from standard CJC-1295, and it is the property most research on the compound is built around.
Published research on CJC-1295 DAC concentrates on Sustained GH Stimulation, Albumin-Depot Mechanism, GHRH Axis Selectivity and Growth Normalization. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes CJC-1295 DAC acting across GHRH Receptor Activation, Albumin Binding — Half-Life Extension and Downstream IGF-1 Elevation, reported respectively as GHRH-R Agonist, DAC Technology and IGF-1 Axis. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
CJC-1295 DAC has a molecular formula of C152H252N44O42 and an average mass of 3367.97 g/mol. It is indexed under CAS 863288-34-0. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. CJC-1295 DAC is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. CJC-1295 DAC is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
